The Hong Kong 18A market has navigated eight years of evolution, moving decisively beyond an era of "story-driven" speculative growth. Following multiple rounds of valuation resets and liquidity divergence, the market's pricing logic has undergone a fundamental reconstruction: shifting focus from chasing elusive long-term potential to anchoring on three core metrics: clinical validation certainty, commercial execution capability, and recognition from global capital. At this pivotal industry inflection point, the IPO of ALEBUND-B (HKEX: 09637) has captured the market's full attention. This innovative biopharmaceutical company, focused on kidney diseases, not only possesses a robust pipeline matrix of "1 commercialized product + 7 clinical-stage drug candidates" but has also assembled an elite group of 11 cornerstone investors spanning global sovereign wealth funds, century-old asset managers, specialized life science funds, and industrial capital, setting a new benchmark for cornerstone investor lineups in the recent history of the 18A market.
The Eight-Year Evolution of 18A: From Bubble to Value Reassessment
Eight years of rigorous market testing have brought the industry to a critical juncture of differentiation. Leading companies have established commercial closed loops and joined the ranks of global innovation, while many others continue to struggle through clinical trials, with some facing halved valuations and dried-up liquidity. The bubble era where "having a target was enough for funding" is definitively over. Capital is rapidly concentrating on core assets with genuine value. The market's screening criteria have become unprecedentedly pragmatic: How many quarters until the core product's commercialization? Can the pipeline generate a continuous stream of catalysts? Does the backing capital possess genuine professional judgment and long-term commitment? These three questions have replaced "market size" and "novelty of mechanism" as the core investment thesis for today's 18A market. ALEBUND-B stands out as a representative company under this new standard. It focuses on kidney diseases and related chronic conditions, building a full-cycle product system covering complication treatment, disease modification, and functional cure.
An Unprecedented Cornerstone Consortium: A Collective Vote by Global Long-Term Capital
Unlike the often-assembled cornerstone lineups of many 18A companies, ALEBUND-B's 11 cornerstone investors present a rare three-tiered structure of consensus. The top tier comprises global sovereign funds and century-old asset managers seeking long-term certainty. The middle tier consists of professional life science capital deeply entrenched in the pharmaceutical sector. The base tier includes industrial capital and leading domestic mutual funds rooted in the Chinese market. More significantly, this cornerstone lineup features three historic "firsts," underscoring ALEBUND-B's global scarcity.
The ultimate endorsement from global long-term capital is evident. GIC, Singapore's sovereign wealth fund managing over US$936 billion, is participating as a cornerstone investor in a Hong Kong 18A company IPO for the first time in recent years, breaking its previous practice of investing only in mature pharmaceutical assets in the secondary market. GIC has been a long-term partner, entering in the B+ funding round and continuing to invest. Echoing this is the century-old US asset management giant Loomis Sayles, with over US$425 billion in assets under management. This marks its first-ever participation as a cornerstone investor in any Hong Kong-listed company, indicating that ALEBUND-B's investment thesis has transcended regional boundaries to enter the core portfolio of top-tier global active management firms.
The participation of specialized life science funds provides the most authoritative validation of the pipeline's value. New York-based RTW Investments, a highly influential global life science investment firm known for "understanding science, clinical development, and capital markets," is a cornerstone investor. Similarly, US-based Cormorant Asset Management, focused on cross-cycle investments in biopharma, is also participating. Notably, SymBiosis, the dedicated biopharmaceutical fund under the Walmart family office, is making its debut as a cornerstone investor in the Hong Kong market, viewing ALEBUND-B as its core strategic investment in the Asian nephrology field.
Local forces add synergistic support. Tencent, the second-largest pre-IPO shareholder with an 11.73% stake, has been a significant investor since the A-round. Its deep industrial resources, digital capabilities, and traffic advantages in healthcare will provide strong support for patient management, digital marketing, and commercialization. The collective participation of leading Chinese mutual funds like E Fund, China Universal, and GF Fund represents firm confidence in the potential of China's kidney disease market and the company's commercial capabilities, providing solid liquidity support post-listing.
The Core Logic of Long-Term Capital Consensus: A Three-Tier Pipeline Fortress
The rare consensus among global top-tier capital stems from ALEBUND-B's unique industry positioning built on a "three-tier pipeline value ladder," perfectly aligning with the risk-return preferences of different capital types.
The first tier provides near-term commercial cash flow certainty. The core product AP301 has completed its pivotal Phase III trial in China, with a New Drug Application submission imminent and expected approval in 2027. Its 52-week response rate significantly outperforms existing standard therapies, positioning it as a potential best-in-class product for hyperphosphatemia. Complementing this is the already commercialized long-acting erythropoiesis-stimulating agent Mesiro®, included in the National Reimbursement Drug List, covering over 50 cities and 300 hospitals nationwide. It generated revenue of RMB 30.6 million in 2025, a 368% year-on-year increase, providing stable cash flow and validating the nephrology-focused commercial team's execution.
The second tier unlocks global growth potential. AP306, the world's first and only clinical-stage pan-phosphate transporter inhibitor, has received Breakthrough Therapy Designation in China. Its Phase II data showed a serum phosphorus control rate nearing 95%, far exceeding existing therapies. Crucially, ALEBUND-B pioneered an innovative global partnership model ("license + equity + industrial collaboration"), co-founding R1 Therapeutics with industrial capital, including global dialysis leader DaVita (a Warren Buffett holding), to advance AP306's global development. This model shares clinical risk while securing overseas channel resources, allowing ALEBUND-B to share in long-term global market returns.
The third tier unlocks multi-billion-dollar long-term valuation. Beyond near-term certainty and mid-term growth, ALEBUND-B is developing frontier pipelines poised to redefine kidney disease treatment. AP303 is a rare global multi-indication CKD disease-modifying drug covering four core subtypes, including Diabetic Kidney Disease (representing 70% of the CKD market), and has received FDA Orphan Drug designation. AP308 is the world's only engineered IgA protease in clinical development, targeting the core pathological mechanism of IgA Nephropathy with the potential for functional cure. Success for these products could fundamentally reshape the global nephrology treatment landscape, leading to a quantum leap in the company's valuation.
Conclusion: A New Benchmark for Value Realization
The Hong Kong 18A market has never lacked stories. What is truly scarce are companies that can systematically translate stories into clinical data, commercial revenue, and global partnerships. The collective endorsement of ALEBUND-B by 11 top-tier institutions is not a fleeting market sentiment but a necessary choice by long-term capital for "value-realizing" biotech. For the entire industry, ALEBUND-B's IPO holds landmark significance. It declares the definitive end of the "story-driven" era and establishes a new benchmark for the "value realization" era. As global long-term capital begins voting with real money for certainty, those innovative pharmaceutical companies possessing genuine clinical value, commercial capability, and a global vision will ultimately navigate through cycles and step into their own spotlight. ALEBUND-B is not an endpoint but a new starting point for the maturation of the 18A market.
Comments